309 related articles for article (PubMed ID: 34885957)
1. A Review of HER4 (ErbB4) Kinase, Its Impact on Cancer, and Its Inhibitors.
El-Gamal MI; Mewafi NH; Abdelmotteleb NE; Emara MA; Tarazi H; Sbenati RM; Madkour MM; Zaraei SO; Shahin AI; Anbar HS
Molecules; 2021 Dec; 26(23):. PubMed ID: 34885957
[TBL] [Abstract][Full Text] [Related]
2. HER4 promotes the growth and metastasis of osteosarcoma via the PI3K/AKT pathway.
Li X; Huang Q; Wang S; Huang Z; Yu F; Lin J
Acta Biochim Biophys Sin (Shanghai); 2020 Apr; 52(4):345-362. PubMed ID: 32181480
[TBL] [Abstract][Full Text] [Related]
3. Discovery of first-in-class imidazothiazole-based potent and selective ErbB4 (HER4) kinase inhibitors.
Zaraei SO; Sbenati RM; Alach NN; Anbar HS; El-Gamal R; Tarazi H; Shehata MK; Abdel-Maksoud MS; Oh CH; El-Gamal MI
Eur J Med Chem; 2021 Nov; 224():113674. PubMed ID: 34237622
[TBL] [Abstract][Full Text] [Related]
4. PI3K/Akt/mTOR inhibitors in cancer: At the bench and bedside.
Alzahrani AS
Semin Cancer Biol; 2019 Dec; 59():125-132. PubMed ID: 31323288
[TBL] [Abstract][Full Text] [Related]
5. ERBB4 promotes the proliferation of gastric cancer cells via the PI3K/Akt signaling pathway.
Xu J; Gong L; Qian Z; Song G; Liu J
Oncol Rep; 2018 Jun; 39(6):2892-2898. PubMed ID: 29620274
[TBL] [Abstract][Full Text] [Related]
6. Prolactin and ErbB4/HER4 signaling interact via Janus kinase 2 to induce mammary epithelial cell gene expression differentiation.
Muraoka-Cook RS; Sandahl M; Hunter D; Miraglia L; Earp HS
Mol Endocrinol; 2008 Oct; 22(10):2307-21. PubMed ID: 18653779
[TBL] [Abstract][Full Text] [Related]
7. Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathways.
Ghayad SE; Vendrell JA; Ben Larbi S; Dumontet C; Bieche I; Cohen PA
Int J Cancer; 2010 Jan; 126(2):545-62. PubMed ID: 19609946
[TBL] [Abstract][Full Text] [Related]
8. Phosphatidylinositol 3-kinase/Akt signaling as a key mediator of tumor cell responsiveness to radiation.
Toulany M; Rodemann HP
Semin Cancer Biol; 2015 Dec; 35():180-90. PubMed ID: 26192967
[TBL] [Abstract][Full Text] [Related]
9. ErbB3 drives mammary epithelial survival and differentiation during pregnancy and lactation.
Williams MM; Vaught DB; Joly MM; Hicks DJ; Sanchez V; Owens P; Rahman B; Elion DL; Balko JM; Cook RS
Breast Cancer Res; 2017 Sep; 19(1):105. PubMed ID: 28886748
[TBL] [Abstract][Full Text] [Related]
10. RNA-binding protein IGF2BP2 enhances circ_0000745 abundancy and promotes aggressiveness and stemness of ovarian cancer cells via the microRNA-3187-3p/ERBB4/PI3K/AKT axis.
Wang S; Li Z; Zhu G; Hong L; Hu C; Wang K; Cui K; Hao C
J Ovarian Res; 2021 Nov; 14(1):154. PubMed ID: 34774079
[TBL] [Abstract][Full Text] [Related]
11. Achieving cancer cell death with PI3K/mTOR-targeted therapies.
Yea SS; Fruman DA
Ann N Y Acad Sci; 2013 Mar; 1280(1):15-8. PubMed ID: 23551096
[TBL] [Abstract][Full Text] [Related]
12. Akt in cancer: Mediator and more.
Revathidevi S; Munirajan AK
Semin Cancer Biol; 2019 Dec; 59():80-91. PubMed ID: 31173856
[TBL] [Abstract][Full Text] [Related]
13. Mechanism of activation and inhibition of the HER4/ErbB4 kinase.
Qiu C; Tarrant MK; Choi SH; Sathyamurthy A; Bose R; Banjade S; Pal A; Bornmann WG; Lemmon MA; Cole PA; Leahy DJ
Structure; 2008 Mar; 16(3):460-7. PubMed ID: 18334220
[TBL] [Abstract][Full Text] [Related]
14. [PI3K inhibitor].
Yano S; Takeuchi S; Yamada T; Mouri H; Yamashita K; Ohtsubo K; Yasumoto K
Gan To Kagaku Ryoho; 2011 Jan; 38(1):23-6. PubMed ID: 21368457
[TBL] [Abstract][Full Text] [Related]
15. Prenatal di-(2-ethylhexyl) phthalate exposure induced myocardial cytotoxicity via the regulation of the NRG1-dependent ErbB2/ErbB4-PI3K/AKT signaling pathway in fetal mice.
Yu D; Zhu D; Wang X; Li B; Li J; Lu P; Ji Y; Wang X
Ecotoxicol Environ Saf; 2022 Aug; 241():113771. PubMed ID: 35716406
[TBL] [Abstract][Full Text] [Related]
16. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
17. Association of PI3K-Akt signaling pathway with digitalis-induced hypertrophy of cardiac myocytes.
Liu L; Zhao X; Pierre SV; Askari A
Am J Physiol Cell Physiol; 2007 Nov; 293(5):C1489-97. PubMed ID: 17728397
[TBL] [Abstract][Full Text] [Related]
18. Potent dual EGFR/Her4 tyrosine kinase inhibitors containing novel (1,2-dithiolan-4-yl)acetamides.
Mansour TS; Pallepati RR; Basetti V
Bioorg Med Chem Lett; 2020 Aug; 30(16):127288. PubMed ID: 32631510
[TBL] [Abstract][Full Text] [Related]
19. The Q43L mutant of neuregulin 2β is a pan-ErbB receptor antagonist.
Wilson KJ; Mill CP; Gallo RM; Cameron EM; VanBrocklin H; Settleman J; Riese DJ
Biochem J; 2012 Apr; 443(1):133-44. PubMed ID: 22216880
[TBL] [Abstract][Full Text] [Related]
20. Dual Inhibition of MEK and PI3K/Akt Rescues Cancer Cachexia through both Tumor-Extrinsic and -Intrinsic Activities.
Talbert EE; Yang J; Mace TA; Farren MR; Farris AB; Young GS; Elnaggar O; Che Z; Timmers CD; Rajasekera P; Maskarinec JM; Bloomston M; Bekaii-Saab T; Guttridge DC; Lesinski GB
Mol Cancer Ther; 2017 Feb; 16(2):344-356. PubMed ID: 27811010
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
